Alkem Laboratories

Alkem Laboratories EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Alkem Laboratories (ALKEM.NS) as of Oct 24, 2026 is 44.50. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 49.75 — a change of -10.56% (lower).

EV/FCF

44.50

YoY

-10.56%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Alkem Laboratories is 2026 44.50 . EV/FCF (Enterprise Value to Free Cash Flow) of Alkem Laboratories was 2025 49.75 . It decreases by -10.56% lower compared to the previous year.

The Alkem Laboratories EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
258.77 INR
Jan 1, 2020
293.77 INR
Jan 1, 2021
59.80 INR
Jan 1, 2022
84.58 INR
Jan 1, 2023
44.29 INR
Jan 1, 2024
36.18 INR
Jan 1, 2025
49.75 INR
Jan 1, 2026
44.50 INR
The Alkem Laboratories EV/FCF history
YEAREV/FCFYoY
44.50-10.56%
49.75+37.51%
36.18-18.31%
44.29-47.63%
84.58+41.43%
59.80-79.64%
293.77+13.52%
258.77-264.73%
-157.09-57.31%
-367.97-368.78%
136.90-60.18%
343.84-0.97%
347.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alkem Laboratories stock

EV/FCF (Enterprise Value to Free Cash Flow) of Alkem Laboratories is 44.50 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Alkem Laboratories changed from 49.75 to 44.50, representing a -10.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Alkem Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alkem Laboratories

All Key Metrics — Alkem Laboratories